We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+28.86%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$661M
AUM Growth
-$82.1M
Cap. Flow
-$38M
Cap. Flow %
-5.74%
Top 10 Hldgs %
98.23%
Holding
19
New
–
Increased
–
Reduced
5
Closed
5

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$10.8M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$8.7M
3
UPB
Upstream Bio Inc
UPB
+$7.52M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.32M
5
KRYS icon
Krystal Biotech
KRYS
+$2.66M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Decheng Capital held 19 positions worth $661M, down 11% from $743M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Decheng Capital withdrew a net $38M in Q1 2026, closing 5 positions and reducing 5 holdings. Its most notable exit was Crinetics Pharmaceuticals, an estimated $4.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Decheng Capital's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $10.8M.
  • Decheng Capital fully exited Crinetics Pharmaceuticals in Q1 2026, selling an estimated $4.32M.
  • Decheng Capital's ten largest holdings make up 98% of its $661M portfolio in Q1 2026.
  • Decheng Capital opened 0 new positions and closed 5 in Q1 2026.
  • Decheng Capital's portfolio value fell 11% quarter-over-quarter to $661M.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.